Item 2.02. Results of Operations and Financial Condition. On August 7, 2025, Iovance Biotherapeutics, Inc. (the “ Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025, and an update on recent developments. A copy of that press release is furnished as Exhibit 99.1. The information furnished under this Item 2.02, including the accompanying Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed to be incorporated by reference in any subsequent filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as specifically stated in such filing.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; As previously disclosed, on August 6, 2025, Corleen Roche was appointed as Chief Financial Officer of the Company. Ms. Roche will replace Matthew W. Rosinack as the Company’s Principal Financial Officer and Principal Accounting Officer, effective the day after the Company files its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Description No. 99.1 Press Release of Iovance Biotherapeutics, Inc., dated August 7, 2025. ────────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data File (embedded as Inline XBRL document) SIGNATURES